Cargando…
Plasma-Based Longitudinal Evaluation of ESR1 Epigenetic Status in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer
BACKGROUND: Endocrine therapy (ET) is the mainstay of treatment for hormone receptor-positive human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer; however, adaptive mechanisms emerge in about 25–30% of cases through alterations in the estrogen receptor ligand-binding do...
Autores principales: | Gerratana, Lorenzo, Basile, Debora, Franzoni, Alessandra, Allegri, Lorenzo, Viotto, Davide, Corvaja, Carla, Bortot, Lucia, Bertoli, Elisa, Buriolla, Silvia, Targato, Giada, Da Ros, Lucia, Russo, Stefania, Bonotto, Marta, Belletti, Barbara, Baldassarre, Gustavo, Damante, Giuseppe, Puglisi, Fabio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7531252/ https://www.ncbi.nlm.nih.gov/pubmed/33072577 http://dx.doi.org/10.3389/fonc.2020.550185 |
Ejemplares similares
-
First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study
por: Basile, Debora, et al.
Publicado: (2021) -
Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside
por: Basile, Debora, et al.
Publicado: (2019) -
CDK4/6 Inhibitors as Upfront Treatment in a Patient with Breast Cancer Presenting with a Clinical Critic Situation: A Case Report and Review of the Literature
por: Targato, Giada, et al.
Publicado: (2022) -
CDK4/6 Inhibitors in Melanoma: A Comprehensive Review
por: Garutti, Mattia, et al.
Publicado: (2021) -
Immunotherapy in NSCLC Patients with Brain Metastases
por: Buriolla, Silvia, et al.
Publicado: (2022)